Discontinued — last reported Q1 '26
UnitedHealth Group Optum Rx — Total revenues decreased by 13.8% to $35.74B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.7%, from $35.13B to $35.74B. Over 4 years (FY 2021 to FY 2025), Optum Rx — Total revenues shows an upward trend with a 14.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Growth indicates successful client acquisition and increased volume in pharmacy services, while a decline may signal competitive pressure or contract losses.
The aggregate top-line revenue generated by the pharmacy benefit management segment, including pharmacy services, drug d...
Comparable to total segment revenue reported by major PBM competitors and diversified healthcare service providers.
unh_segment_optum_rx_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $22.52B | $23.34B | $23.85B | $23.91B | $24.81B | $25.20B | $25.85B | $27.42B | $28.65B | $28.86B | $31.17B | $30.84B | $32.42B | $34.21B | $35.77B | $35.13B | $38.46B | $39.68B | $41.46B | $35.74B |
| QoQ Change | — | +3.6% | +2.2% | +0.3% | +3.7% | +1.6% | +2.6% | +6.0% | +4.5% | +0.7% | +8.0% | -1.1% | +5.1% | +5.5% | +4.6% | -1.8% | +9.5% | +3.2% | +4.5% | -13.8% |
| YoY Change | — | — | — | — | +10.1% | +8.0% | +8.4% | +14.7% | +15.5% | +14.5% | +20.5% | +12.5% | +13.2% | +18.5% | +14.8% | +13.9% | +18.6% | +16.0% | +15.9% | +1.7% |